Shares of Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) fell 2.1% during trading on Monday . The stock traded as low as $1.39 and last traded at $1.40. 87,563 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 191,905 shares. The stock had previously closed at $1.43.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Vivani Medical in a report on Tuesday, September 2nd. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $4.00.
Get Vivani Medical alerts:
View Our Latest Stock Analysis on Vivani Medical
Vivani Medical Trading Down 2.1%
The company has a market capitalization of $82.94 million, a price-to-earnings ratio of -3.11 and a beta of 3.12. The stock’s fifty day simple moving average is $1.34 and its 200-day simple moving average is $1.21.
Vivani Medical (NASDAQ:VANI – Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, analysts anticipate that Vivani Medical, Inc. will post -0.41 EPS for the current fiscal year.
Insider Transactions at Vivani Medical
In other news, Director Gregg Williams acquired 2,068,453 shares of the company’s stock in a transaction on Monday, September 15th. The shares were bought at an average cost of $1.16 per share, with a total value of $2,399,405.48. Following the transaction, the director owned 15,909,348 shares in the company, valued at approximately $18,454,843.68. This trade represents a 14.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 46.40% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Vivani Medical
A number of large investors have recently modified their holdings of the company. Northern Trust Corp increased its position in shares of Vivani Medical by 19.1% in the 4th quarter. Northern Trust Corp now owns 71,915 shares of the company’s stock valued at $83,000 after purchasing an additional 11,540 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of Vivani Medical in the 2nd quarter valued at approximately $25,000. Jane Street Group LLC purchased a new stake in shares of Vivani Medical in the 4th quarter valued at approximately $66,000. Wealthedge Investment Advisors LLC increased its position in shares of Vivani Medical by 238.8% in the 1st quarter. Wealthedge Investment Advisors LLC now owns 125,033 shares of the company’s stock valued at $131,000 after purchasing an additional 88,132 shares during the last quarter. Finally, Connective Capital Management LLC increased its position in shares of Vivani Medical by 796.2% in the 1st quarter. Connective Capital Management LLC now owns 162,098 shares of the company’s stock valued at $170,000 after purchasing an additional 144,010 shares during the last quarter. 6.78% of the stock is owned by hedge funds and other institutional investors.
About Vivani Medical
(Get Free Report)
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Recommended Stories
Five stocks we like better than Vivani Medical
Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
Stock Market Upgrades: What Are They?
Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
Diversification Can Smooth Returns And Mitigate Portfolio Risk
This ETF Weeds Out Small-Cap Underperformers
Vivani Medical (NASDAQ:VANI) Trading Down 2.1% – Should You Sell?
